The symptoms of sedative/hypnotic toxidrome include ataxia , blurred vision, coma , confusion , delirium , deterioration of central nervous system functions, diplopia , dysesthesias , hallucinations , nystagmus , paresthesias , sedation , slurred speech, and stupor . Apnea is a potential complication. Substances that may cause this toxidrome include anticonvulsants , barbiturates , benzodiazepines , gamma-Hydroxybutyric acid , Methaqualone , and ethanol . While most sedative-hypnotics are anticonvulsant , some such as GHB and methaqualone instead lower the seizure threshold, and so can cause paradoxical seizures in overdose.
There is no compelling evidence that salbutamol and other β 2 agonists can increase performance in healthy athletes.  In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen."  
The effects of overdosage with DuoNeb (ipratropium bromide and albuterol sulfate) are expected to be related primarily to albuterol sulfate, since ipratropium bromide is not well-absorbed systemically after oral or aerosol administration. The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of symptoms such as seizures, angina , hypertension or hypotension , tachycardia with rates up to 200 beats per minute, arrhythmia , nervousness, headache, tremor , dry mouth , palpitation, nausea , dizziness, fatigue , malaise , insomnia , and exaggeration of pharmacological effects listed in ADVERSE REACTIONS. Hypokalemia may also occur. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse of DuoNeb (ipratropium bromide and albuterol sulfate) . Treatment consists of discontinuation of DuoNeb (ipratropium bromide and albuterol sulfate) together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of DuoNeb (ipratropium bromide and albuterol sulfate) .